In vivo studies show that F4/80+ CD169+ medullary sinus macrophages and F4/80+ CD169− medullary cord macrophages have the ability of cross-presentation because only these cells can stimulate tumor-specific CD8+ T lymphocytes when targeted by a nanogel loaded with tumor-specific synthetic long peptide antigen (LPA) and a Toll-like receptor (TLR) 9 agonist [25]. This evidence concerns the gene SIGLEC1 and neoplasm.